At the J.P. Morgan Healthcare Conference in January, Teladoc CEO Jason Gorevic dismissed the growing chorus of naysayers, expressing confidence in his company’s trajectory and asserting, “I think that we are probably still underappreciated with respect to our market advantage, the financial performance that we’ve demonstrated, as well as the bright outlook we have in terms of our growth potential going forward.”
Barely three months later, Teladoc announced that Gorevic, the charismatic face of the company for 15 years, was gone, leaving the telehealth pioneer scrambling to appease investors.
In an examination by STAT, analysts and officials who worked with Gorevic said the departure follows a series of missed financial projections, a precipitous decline in Teladoc’s stock price, and an uninspired vision for its future.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect